Buy 10x Genomics

Logo for stock TXG (10x Genomics)

Amount

£
GBP

Latest price

$11.41
(£1.00 = $1.334)

Number of shares (est.)

0

Start investing today

Open an investment account in Emma and enjoy commission free stock trading. Capital at risk, other charges apply.

QR code linking to downloads for the Emma app.
Download on the App Store buttonGet it on Google Play button

Metrics

Market Cap

$1.458B

P/E ratio

-16.83

EPS

-$0.696

Beta

2.12

Dividend rate

N/A

Dividend yield

N/A

About

10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.

CEO

Mr. Serge Wilson Saxonov, Ph.D.

Employees

1,306

Sector

Industrials

Company HQ

PLEASANTON, United States of America

News

Logo for news article #0 (10x Genomics to Report Third Quarter 2025 Financial Results on November 6, 2025)

10x Genomics to Report Third Quarter 2025 Financial Results on November 6, 2025

PLEASANTON, Calif. , Oct. 9, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced it will report financial results for the third quarter ended September 30, 2025 after market close on Thursday, November 6, 2025.

PRNewsWire

October 09, 2025

Logo for news article #1 (Parse Biosciences Invalidates Scale Biosciences (now 10x Genomics) Patent)

Parse Biosciences Invalidates Scale Biosciences (now 10x Genomics) Patent

SEATTLE--(BUSINESS WIRE)--Parse Biosciences Invalidates Scale Biosciences (now 10x Genomics) Patent.

Business Wire

October 09, 2025

Logo for news article #2 (10x Genomics, Inc. (TXG) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript)

10x Genomics, Inc. (TXG) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

10x Genomics, Inc. (NASDAQ:TXG ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 11:30 AM EDT Company Participants Serge Saxonov - Co-Founder, CEO & Director Conference Call Participants Yih-Ming Tu - Morgan Stanley, Research Division Presentation Yih-Ming Tu Research Associate Good morning, everyone. Welcome to day 3 of the Morgan Stanley Global Healthcare Conference.

Seeking Alpha

September 10, 2025

Emma logo
Facebook logoTiktok logoTwitter / X logoInstagram logo

© 2025 Emma Technologies Ltd. All Rights Reserved.

Emma is registered and incorporated in England and Wales.

Emma Technologies Ltd is an appointed representative of RiskSave Technologies Ltd, which is authorised and regulated by the Financial Conduct Authority (FRN 775330).

Payment services (Non MIFID or Deposit related products) for Emma Technologies Ltd are provided by The Currency Cloud Limited. Registered in England No. 06323311. Registered Office: Stewardship Building 1st Floor, 12 Steward Street London E1 6FQ. The Currency Cloud Limited is authorised by the Financial Conduct Authority under the Electronic Money Regulations 2011 for the issuing of electronic money (FRN: 900199). For more detail on how your money is protected please see here. You can also find Currency Cloud's Terms of Use here.

Emma Technologies is an Introducer Appointed Representative of Quint Group Limited and not a lender. Quint Group Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 669450). Monevo Limited is an Appointed Representative of TransUnion International UK Limited. TransUnion is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 737740). Emma Technologies introduces customers first to Quint Group Limited, as a licensed credit broker, who then refers on to Monevo Limited.

Emma is registered with the Financial Conduct Authority under the Payment Services Regulations 2017 for the provision of payment services.

Financial Conduct Authority Reg Nr: 794952.
Company Registration Number: 10578464.
Data Protection Registration Number: ZA241546.

All testimonials, reviews, opinions or case studies presented on our website may not be indicative of all customers. Results may vary and customers agree to proceed at their own risk.